CareDx, Inc.
CDNANasdaq
$39.73
↓ -1.5%Jul 17 close · end-of-day
Price
1Y↑ +106.9%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$2.1B
Enterprise Value
$1.9B
P/E
—
P/S
5.1
P/B
6.7
EV/EBITDA
—
PEG
—
FCF Yield
—
Dividend Yield
—
Revenue (TTM)
$412.8M
Net Income (TTM)
-$8.2M
Free Cash Flow (TTM)
—
Gross Margin
—
Operating Margin
-3.9%
Net Margin
-2.0%
ROE
-2.6%
ROIC
-10.1%
Debt / Equity
—
Net Cash
$187.2M
Return 1Y
+236.4%
Company profile
CareDx, Inc. discovers, develops, and commercializes diagnostic solutions for transplant patients and caregivers. It provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients. AlloSeq Tx, a high-resolution HLA typing solution, is used to type human leukocyte antigen (HLA) alleles.
- CEO
- Reginald Seeto
- Sector
- Services
- Industry
- Healthcare
- Employees
- 740
- Headquarters
- California
- Website
- caredx.com
Management & directors
- Hanna John Walter JrPresident and CEO
- Kennedy KeithChief Operating Officer
- Meng JessicaChief Commercial Officer
- Novack Jeffrey AdamSecretary and General Counsel
- Smith NathanChief Financial Officer
- Jain AbhishekChief Financial Officer
Roles derived from SEC Form 4 filings.
Earnings
CDNA Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$117.7M↑ +39.0%
Diluted EPS$0.05↓ -126.3%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $192.2M | $296.4M | $321.8M | $280.3M | $333.8M | $379.8M |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$22.5M | -$29.7M | -$77.2M | -$203.4M | $40.8M | -$30.8M |
| Net income | -$18.7M | -$30.7M | -$76.6M | -$190.3M | $52.5M | -$21.4M |
| Diluted EPS | -$0.40 | -$0.59 | -$1.44 | -$3.54 | $0.93 | -$0.40 |
| Operating cash flow | $33.4M | -$19.3M | -$25.2M | -$18.4M | $38.0M | $42.0M |
| Free cash flow | — | — | — | — | — | — |
| Gross margin | — | — | — | — | — | — |
| Operating margin | -11.7% | -10.0% | -24.0% | -72.5% | 12.2% | -8.1% |
| Net margin | -9.7% | -10.3% | -23.8% | -67.9% | 15.7% | -5.6% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $92.3M | $82.9M | $86.6M | $84.7M | $86.7M | $100.1M | $108.4M | $117.7M |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$7.3M | -$13.7M | $84.4M | -$13.4M | -$11.1M | -$246,000.00 | -$6.0M | $1.2M |
| Net income | -$4.6M | -$10.6M | $87.7M | -$10.4M | -$8.6M | $1.7M | -$4.1M | $2.8M |
| Diluted EPS | -$0.09 | -$0.20 | $1.60 | -$0.19 | -$0.16 | $0.03 | -$0.08 | $0.05 |
| Operating cash flow | $18.9M | $12.5M | $21.9M | -$26.6M | $9.9M | $37.4M | $21.4M | $4.3M |
| Free cash flow | — | — | — | -$28.2M | — | — | — | $514,000.00 |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | -7.9% | -16.6% | 97.5% | -15.8% | -12.8% | -0.2% | -5.6% | 1.0% |
| Net margin | -5.0% | -12.8% | 101.3% | -12.2% | -9.9% | 1.7% | -3.8% | 2.4% |
Company news
Jul 18, 2026
- 2d agoCareDx (CDNA) Is Up 39.4% After Medicare Clarifies Transplant Test Coverage Limits - What's Changedfinance.yahoo.com
- 2d agoCareDx (CDNA) Secures Medicare Reimbursement Clarity, Is The Upside Already Priced In?finance.yahoo.com
- 2d agoCareDx (CDNA) Stock May Be Fully Valued Despite Medicare Coverage Newsfinance.yahoo.com
Jul 16, 2026
- 4d agoCareDx shares jump as Medicare finalizes transplant testing coverage policy (CDNA)investorshub.advfn.com
- 4d agoCareDx to Report Second Quarter 2026 Financial Results on July 30, 2026finance.yahoo.com
- 4d agoCareDx Announces Finalization of Solid Organ Transplant Molecular Testing Local Coverage Determinationfinance.yahoo.com
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-07-16 | Hanna John Walter JR· President and CEO | Sale | 68,000 | $39.01 | $2.7M | filing |
| 2026-07-16 | Hanna John Walter JR· President and CEO | Sale | 50,000 | $36.11 | $1.8M | filing |
| 2026-07-16 | Valantine Hannah | Sale | 28,679 | $36.14 | $1.0M | filing |
| 2026-07-16 | Hanna John Walter JR· President and CEO | Option exercise | 118,000 | $8.20 | $967,600.00 | filing |
| 2026-07-16 | Valantine Hannah | Option exercise | 16,048 | $14.19 | $227,721.12 | filing |
| 2026-07-16 | Valantine Hannah | Option exercise | 7,606 | $20.56 | $156,379.36 | filing |
| 2026-07-16 | Valantine Hannah | Option exercise | 5,125 | $7.96 | $40,795.00 | filing |
| 2026-07-16 | Valantine Hannah | Sale | 100 | $36.55 | $3,655.00 | filing |
| 2026-07-02 | Goldberg Michael | Award | 1,746 | $0.00 | $0.00 | filing |
| 2026-07-01 | Hanna John Walter JR· President and CEO | Tax withholding | 8,511 | $29.25 | $248,946.75 | filing |
| 2026-07-01 | Kennedy Keith· CFO & COO | Tax withholding | 2,930 | $29.25 | $85,702.50 | filing |
| 2026-07-01 | Meng Jessica· Chief Commercial Officer | Tax withholding | 2,411 | $29.25 | $70,521.75 | filing |
| 2026-07-01 | Novack Jeffrey Adam· Secretary and General Counsel | Tax withholding | 997 | $29.25 | $29,162.25 | filing |
| 2026-06-29 | Hanna John Walter JR· President and CEO | Sale | 39,900 | $29.24 | $1.2M | filing |
| 2026-06-29 | Hanna John Walter JR· President and CEO | Option exercise | 39,900 | $8.20 | $327,180.00 | filing |
| 2026-06-26 | Hanna John Walter JR· President and CEO | Sale | 100 | $29.00 | $2,900.00 | filing |
| 2026-06-26 | Hanna John Walter JR· President and CEO | Option exercise | 100 | $8.20 | $820.00 | filing |
| 2026-06-15 | Hanna John Walter JR· President and CEO | Sale | 17,683 | $24.03 | $424,876.51 | filing |
| 2026-06-15 | Valantine Hannah | Sale | 12,103 | $23.11 | $279,728.17 | filing |
| 2026-06-15 | Hanna John Walter JR· President and CEO | Option exercise | 15,676 | $8.20 | $128,543.20 | filing |
| 2026-06-12 | Gunasekaran Suresh | Award | 9,795 | $0.00 | $0.00 | filing |
| 2026-06-12 | Bickerstaff George | Award | 9,795 | $0.00 | $0.00 | filing |
| 2026-06-12 | Goldberg Michael | Award | 9,795 | $0.00 | $0.00 | filing |
| 2026-06-12 | Valantine Hannah | Award | 9,795 | $0.00 | $0.00 | filing |
| 2026-06-12 | COURNOYER CHRISTINE | Award | 9,795 | $0.00 | $0.00 | filing |
Showing the latest 25 transactions — full history in the linked SEC filings.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.